<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80895</article-id><article-id pub-id-type="doi">10.7554/eLife.80895</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>A DARPin-based molecular toolset to probe gephyrin and inhibitory synapse biology</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-284510"><name><surname>Campbell</surname><given-names>Benjamin FN</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284511"><name><surname>Dittmann</surname><given-names>Antje</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284512"><name><surname>Dreier</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-276379"><name><surname>Plückthun</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-29670"><name><surname>Tyagarajan</surname><given-names>Shiva K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0074-1805</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Institute of Pharmacology and Toxicology</institution>, <institution>University of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff2"><institution content-type="dept">Functional Genomics Centre</institution>, <institution>University of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff3"><institution content-type="dept">Department of Biochemistry</institution>, <institution>University of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13947"><name><surname>Huguenard</surname><given-names>John R</given-names></name><role>Reviewing editor</role><aff><institution>Stanford University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>tyagarajan@pharma.uzh.ch</email> (ST);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>10</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e80895</elocation-id><history><date date-type="received"><day>08</day><month>06</month><year>2022</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Campbell et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Campbell et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80895-v1.pdf"/><abstract><p>Neuroscience currently requires the use of antibodies to study synaptic proteins, where antibody binding is used as a correlate to define the presence, plasticity, and regulation of synapses. Gephyrin is an inhibitory synaptic scaffolding protein used to mark GABAergic and glycinergic postsynaptic sites. Despite the importance of gephyrin in modulating inhibitory transmission, its study is currently limited by the tractability of available reagents. Designed Ankyrin Repeat Proteins (DARPins) are a class of synthetic protein binder derived from diverse libraries by <italic>in vitro</italic> selection, and tested by high-throughput screening to produce specific binders. In order to generate a functionally diverse toolset for studying inhibitory synapses, we screened a DARPin library against gephyrin mutants representing both phosphorylated and dephosphorylated states. We validated the robust use of anti-gephyrin DARPin clones for morphological identification of gephyrin clusters in rat neuron culture and mouse brain tissue, discovering previously overlooked clusters. This DARPin-based toolset includes clones with heterogenous gephyrin binding modes that allowed for identification of the most extensive gephyrin interactome to date, and defined novel classes of putative interactors, creating a framework for understanding gephyrin's non-synaptic functions. This study demonstrates anti-gephyrin DARPins as a versatile platform for studying inhibitory synapses in an unprecedented manner.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>310030_192522 /1</award-id><principal-award-recipient><name><surname>Tyagarajan</surname><given-names>Shiva K</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>310030_192689</award-id><principal-award-recipient><name><surname>Plückthun</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Andreas Plückthun, is a cofounder and shareholder of Molecular Partners, who are commercializing the DARPin technology..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The collection of embryonic and adult tissue was performed in accordance with the European Community Council Directives of November 24th 1986 (86/609/EEC). Tissue collection was performed under license ZH011/19 approved by the Cantonal Veterinary office of Zurich.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All relevant mass spectrometry data has been deposited to the ProteomeXchange Consortium via the PRIDE (http://www.ebi.ac.uk/pride) partner repository.Project Name: Gephyrin interactome from mouse brain lysates using anti-gephyrin antibody and anti-gephyrin DARPinsProject accession: PXD033641Project DOI: 10.6019/PXD033641</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Campbell BFN</collab><collab>Dittmann A</collab><collab>Dreier B</collab><collab>Plückthun A</collab><collab>and Tyagarajan SK</collab></person-group><year iso-8601-date="2022">2022</year><source>Gephyrin interactome from mouse brain lysates using anti-gephyrin antibody and anti-gephyrin DARPins</source><ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/pride">http://www.ebi.ac.uk/pride</ext-link><comment>PRIDE, PXD033641</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-80895-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>